MedicaidPrior AuthMedium impact
Liposomal doxorubicin (Revised)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has updated prior authorization requirements for liposomal doxorubicin (Doxil, Lipodox) effective December 1, 2025. The policy expands coverage criteria for six oncology conditions including lymphomas, breast cancer, Kaposi's sarcoma, multiple myeloma, and ovarian cancer with specific combination therapy requirements.
Action Required
Before December 1, 2025: Oncology billing staff must update prior authorization procedures for liposomal doxorubicin (Doxil, Lipodox) for Indiana Medicaid patients. Review the six covered indications and specific combination therapy requirements. Ensure providers document qualifying diagnoses and treatment protocols before submitting prior auth requests. Claims without proper authorization will be denied.